Indaptus Therapeutics, Inc.
NASDAQ: INDP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Junyi Dai
- Employees
- 7
- Headquarters
- New York City, United States
- IPO year
- 2015
- Market cap
- $6.2M
- Website
- https://indaptusrx.com
Loading INDP…
Loading profile data…Frequently asked questions about INDP
What does Indaptus Therapeutics, Inc. (INDP) do?
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evalu...
Where does INDP trade?
Indaptus Therapeutics, Inc. (INDP) trades on the NASDAQ Capital Market.
What sector is INDP in?
Indaptus Therapeutics, Inc. (INDP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Indaptus Therapeutics, Inc.?
Junyi Dai is the chief executive officer of Indaptus Therapeutics, Inc. (INDP).
Where is Indaptus Therapeutics, Inc. headquartered?
Indaptus Therapeutics, Inc. is headquartered in United States.
Does INDP pay a dividend?
Indaptus Therapeutics, Inc. (INDP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did INDP go public?
Indaptus Therapeutics, Inc. (INDP) completed its initial public offering in 2015.